Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
Objective To investigate the short-term efficacy and safety of enzalutamide in the treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer (mCRPC). Methods A total of 31 patients with abiraterone-resistant mCRPC who attended The Affiliated Hospital of Qingdao...
Saved in:
| Main Author: | MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Precision Medicine
2025-02-01
|
| Series: | 精准医学杂志 |
| Subjects: | |
| Online Access: | https://jpmed.qdu.edu.cn/fileup/2096-529X/PDF/1744957524496-1861649341.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01) -
Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01) -
SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
by: Sabin Göktaş Aydın, et al.
Published: (2023-03-01) -
Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01) -
A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)